Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10:13:828565.
doi: 10.3389/fphar.2022.828565. eCollection 2022.

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review

Anna Licata  1 , Maria Giovanna Minissale  1 , Simona Stankevičiūtė  1 , Judith Sanabria-Cabrera  2   3 , Maria Isabel Lucena  2   3   4 , Raul J Andrade  4   4 , Piero Luigi Almasio  1
Affiliations

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review

Anna Licata et al. Front Pharmacol. .

Abstract

Aims: N-Acetylcysteine (NAC) is used as an antidote in acetaminophen (APAP) overdose to prevent and mitigate drug-induced liver injury (DILI). Our objective was to systematically review evidence of the use of NAC as a therapeutic option for APAP overdose and APAP-related DILI in order to define the optimal treatment schedule and timing to start treatment. Methods: Bibliographic databases (PubMed, Web of Science, Embase, and MEDLINE) were searched for retrospective and prospective cohort studies, case series, and clinical trials. The prespecified primary outcomes were DILI-related mortality, hepatotoxicity, and adverse events (AEs). Results: In total, 34 studies of NAC usage in APAP-related DILI cases with 19,580 patients were identified, of which 2,376 patients developed hepatotoxicities. The mortality rate across different studies ranged from 0 to 52%. Large variability of NAC regimens was found, i.e., intravenous (I.V.) (100-150 mg/kg) and oral (70-140 mg/kg), and length of treatment varied-12, 24, or 48 h for I.V. regimen and 72 h for oral administration. The timing of initiation of NAC treatment showed different results in terms of occurrence of hepatotoxicity and mortality; if started within 8 h and no more than 24 h from APAP overdose, either intravenously or orally, NAC administration was efficacious in terms of mortality. The most frequent AEs reported were anaphylactic reactions, followed by cutaneous AEs for the IV route and intestinal AEs for the oral one. Conclusion: NAC improves hepatotoxicity and reduces mortality. Timing of treatment, ranging from 8 to 24 h from APAP overdose, regardless of the regimen or route of administration, is important to prevent or minimize liver damage, particularly in children and in elderly and obese patients.

Keywords: N-acetyl-cysteine; acetaminophen; drug-induced liver injury; hepatotoxicity; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow diagram of the report selection of the current analysis.
See this image and copyright information in PMC

References

    1. Akakpo J., Ramachandran A., Jaeschke H. (2020). Strategies for the Treatment of Acetaminophen Hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 16, 1039–1050. 10.1080/17425255.2020 - DOI - PMC - PubMed
    1. Alhelail M. A., Hoppe J. A., Rhyee S. H., Heard K. J. (2011). Clinical Course of Repeated Supratherapeutic Ingestion of Acetaminophen. Clin. Toxicol. (Phila) 49, 108–112. 10.3109/15563650.2011.554839 - DOI - PubMed
    1. Bateman D. N. (2015). Changing the Management of Paracetamol Poisoning. Clin. Ther. 37, 2135–2141. 10.1016/j.clinthera.2015.07.012 - DOI - PubMed
    1. Bateman D. N., Dear J. W., Thanacoody H. K., Thomas S. H., Eddleston M., Sandilands E. A., et al. (2014). Reduction of Adverse Effects from Intravenous Acetylcysteine Treatment for Paracetamol Poisoning: a Randomised Controlled Trial. Lancet 383, 697–704. 10.1016/S0140-6736(13)62062-0 - DOI - PubMed
    1. Bernal W., Auzinger G., Dhawan A., Wendon J. (2010). Acute Liver Failure. Lancet 376, 190–201. 10.1016/S0140-6736(10)60274-7 - DOI - PubMed

Publication types